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Background: The chemotherapy resistance of non-small cell lung cancer (NSCLC) remains a clinic challenge and is
closely associated with several biomarkers including epidermal growth factor receptor (EGFR) ( Drugs 72(Suppl
1):28–36, 012.), p53 ( Med Sci Monit 11(6):HY11–HY20, 2005.) and excision repair cross complementing gene 1
(ERCC1) ( J Thorac Oncol 8(5):582–586, 2013.). Fluorodeoxyglucose positron emission tomography (FDG–PET) is the
best non-invasive surrogate for tumor biology with the maximal standardized uptake values (SUVmax) being the
most important paradigm. However, there are limited data correlating FDG-PET with the chemotherapy resistant
tumor markers. The purpose of this study was to determine the correlation of chemotherapy related tumor marker
expression with FDG–PET SUVmax in NSCLC.
Methods: FDG–PET SUVmax was calculated in chemotherapy naïve patients with NSCLC (n = 62) and
immunohistochemical analysis was performed for EGFR, p53 or ERCC1 on the intraoperative NSCLC tissues. Each
tumor marker was assessed independently by two pathologists using common grading criteria. The SUVmax
difference based on the histologic characteristics, gender, differentiation, grading and age as well as correlation
analysis among these parameters were performed. Multiple stepwise regression analysis was further performed to
determine the primary predictor for SUVmax and the receiver operating characteristics (ROC) curve analysis was
performed to detect the optimized sensitivity and specificity for SUVmax in suggesting chemotherapy resistant
tumor markers.
Results: The significant tumor type (P = 0.045), differentiation (P = 0.021), p53 (P = 0.000) or ERCC1 (P = 0.033)
positivity dependent differences of SUVmax values were observed. The tumor differentiation is significantly
correlated with SUVmax (R = −0.327), tumor size (R = −0.286), grading (R = −0.499), gender (R = 0.286) as well as the
expression levels for p53 (R = −0.605) and ERCC1 (R = −0.644). The expression level of p53 is significantly correlated
with SUVmax (R = 0.508) and grading (R = 0.321). Furthermore, multiple stepwise regression analysis revealed that
p53 expression was the primary predictor for SUVmax. When the cut-off value of SUVmax was set at 5.15 in the ROC
curve analysis, the sensitivity and specificity of SUVmax in suggesting p53 positive NSCLC were 79.5% and 47.8%,
respectively.
Conclusion: The current study suggests that SUVmax of primary tumor on FDG-PET might be a simple and good
non-invasive method for predicting p53-related chemotherapy resistance in NSCLC when we set the cu-off value of
SUVmax at 5.15.
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Lung cancer is the most frequently diagnosed cancer
and leads to the most cancer mortality worldwide
which accounts for almost 1.3 million deaths a year
[1]. Nearly 85% of lung cancer cases are represented
by non-small cell lung cancer (NSCLC) with the
early diagnosis and effective therapy being two main
issues [2].
Although significant therapeutic advances have been
achieved, poor prognosis and short survival time of
patients, as well as the limited value of any sort of
conventional therapy are the current dilemma for
NSCLC therapy [3]. Platinum-based adjuvant che-
motherapy is usually recommended after surgical re-
section of NSCLC with good performance status and
completely resected stage IB-IIIA disease [4]. Such
combinational therapy did improve the survival for
some patients with early-stage NSCLC [5-7]. However,
a large population remains resistant to chemotherapy
[8], which has also been confirmed in NSCLC tumor
culture study [9]. Increasing evidences advocate the
concept that some molecular markers including epi-
dermal growth factor receptor (EGFR) [10], p53 [11]
and excision repair cross complementing gene 1
(ERCC1) [12] are associated with chemotherapy resis-
tance in NSCLC. Clarifying the relationship of these
molecular markers with noninvasive diagnostic me-
thods is important for the planning of therapeutic
strategy.
Fluorodeoxyglucose positron emission tomography
(FDG–PET) has become an important non-invasive tool
for diagnosing and staging in NSCLC. FDG–PET maximal
standardized uptake values (SUVmax) of primary tumors
have been shown to correlate with both stage and nodal
disease in NSCLC [13]. Several studies have reported the
relationship between the SUVmax and the expression levels
of some biomarkers, such as Glut 1[14], COX-2[15], Ki-67
[16] and vascular endothelial growth factor (VEGF) [17].
Thus we hypothesized that the SUVmax of FDG has some
close relationship with the chemotherapy resistance asso-
ciated biomarkers and can serve as a tool to predict some
specific chemotherapy résistance for better planning the
individualized therapeutic strategy.
The purpose of this study is to examine the relation-
ship between the expressions of chemotherapy re-
sistance related tumor markers and FDG–PET. The
SUVmax difference based on the histologic characteris-
tics, gender, differentiation, grading and age as well as
correlation analysis among these parameters were per-
formed. Multiple stepwise regression analysis was fur-
ther performed to determine the primary predictor for
SUVmax. Collectively, the current study will offer insight
into the relationships between expression of these spe-
cific tumor markers and FDG–PET in NSCLC.Methods
Study population
Sixty-two patients with diagnosed NSCLC by biopsy
(38/62) or operation (24/62) who were naïve to chemo-
therapy from the cancer center of our hospital from
January 1, 2011 to December 31, 2012 were enrolled in
this study. The FDG-PET/CT was performed within one
week before biopsy or operation. The histological type was
determined according to the World Health Organization
(WHO) criteria [18] and the tumor–node–metastasis
(TNM) staging system was used according to the criteria
in 2011.
Paraffin-embedded primary lung tumor samples were
obtained from the pathological department of our hos-
pital. All tissue sections were reviewed for histological type
and graded by two pathologists blinded to FDG-PET
results. Written informed consent was obtained from each
enrolled patient for the study of the excised tissue. This
study was conducted with the approval of the institutional
ethics committee of the First Affiliated Hospital of Xi’an
Jiaotong University.
18 F-FDG PET/CT
Patients were fasted for 6 hours prior to imaging. FDG-
PET images were obtained at 40 min after FDG injec-
tion (3.7 MBq /kg) with a PET/CT system (GEMINI
64TF, Philips, Cleveland, USA). Non-contrast CT scan
was performed prior to the PET scan with the multide-
tector spiral CT scanner. PET scan was performed im-
mediately with an acquisition time of 2.0 min/bed
position during shallow breathing with the scan field
limited from head up to the upper tights. Diagnostic CT
scan of chest with respiratory control was performed on
the same PET/CT system. Co-registered images were
displayed by means of SYNTEGRA software (Philips
Medical Systems).
PET/CT images were evaluated by two nuclear physi-
cians in a blinded manner. The SUVmax was determined
by drawing region of interest (ROI) around the primary
tumor on the transaxial slices, and calculated using the
following equation: tumor activity concentrationinjected dose=body weight .
Immunohistochemical analysis
Immunohistochemical analysis was performed on paraf-
fin-embedded lung cancer tissues. Information of the anti-
body, dilution and staining pattern were summarized in
Table 1. The sections were examined by 2 investigators
who had no knowledge of the corresponding clinical pa-
thologic data. For p53 (Figure 1E) and ERCC1 (Figure 1F),
nucleus and/or cytoplasm staining was considered posi-
tive. EGFR was considered positive when cell membrane
and/or cytoplasm staining was observed (Figure 1D).
Intensity of staining was scored as the following:
Table 1 Antibodies used for immunohistochemical analysis
Antibody Company Catolog# Clone Dilution Positive staining pattern
EGFR Invitrogen ZM-0083 31G7 1:100 Cytomembrane/Cytoplasm
p53 Invitrogen ZM-0408 BP53.12 1:50 Nucleus
ERCC1 Invitrogen ZM-0138 4 F9 1:50 Nucleus/Cytoplasm
EGFR = epidermal growth factor receptor; ERCC1 = excision repair cross complementing gene 1.
Duan et al. BMC Cancer 2013, 13:546 Page 3 of 8
http://www.biomedcentral.com/1471-2407/13/5460 (no staining), 1+ (weak staining), 2 + (intermediate stai-
ning), 3 + (strong staining). The percentage of positive
cells was scored as 0 (0%), 1 (1% to 9%), 2 (10% to 49%),
and 3 (50% to 100%) for ERCC1 and p53. For EGFR, it is
0 (0%), 1 (1% to 9%), 2 (10% to 25%), and 3 (>25%). The
immunohistochemistry (IHC) score (0 to 9) was defined
according to the product intensity and percentage of posi-
tive cells. We categorized the patients into four groups
according to IHC score (0, 1 to 3, 4 to 6, 7 to 9). TheFigure 1 Representative images of PET-CT and immunohistochemistr
PET and CT images. Immunohistochemical stainings for (D) epidermal grow
complementing gene 1(ERCC1). (magnification, ×400).biomarkers expression was judged as positive when the
IHC score was greater than or equal to 1 (groups 2, 3
and 4) (Figure 1D, E and F). EGFR, p53 and ERCC1
were positive in 43.5%, 62.9% and 67.7% NSCLCs.
Statistical analysis
Statistical analysis was performed using SPSS software,
version 17.0 (SPSS Inc, Chicago, IL). The results were
expressed as mean ± standard error mean (SEM). They. Transaxial images of (A) diagnostic CT, (B) FDG-PET and (C) fusion of
th factor receptor (EGFR), (E) p53 and (F) excision repair cross







< 60 25 6.81 ± 0.61
≥ 60 37 8.83 ± 0.83
Gender 0.147
Male 47 8.48 ± 0.64
Female 15 6.57 ± 1.13
Tumor size (diameter) 0.064
< 3 cm 14 6.10 ± 0.80
≥ 3 cm 48 8.58 ± 0.67
Tumor differentiation 0.021
Well 11 4.85 ± 0.69
Moderate 20 8.10 ± 1.81
Poor 31 9.09 ± 0.85
Tumor type 0.045
Adenocarcinoma 22 9.53 ± 1.01
Squamous cell carcinoma 40 7.19 ± 0.64
Stage 0.612
I 10 6.35 ± 1.77
II 9 8.27 ± 2.76
III 19 8.06 ± 0.77
IV 24 8.59 ± 1.01
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pendent differences were tested using student t-test or
one way analysis of the variable (ANOVA) followed by
LSD post hoc test. Spearman correlation analysis was
used to determine the relationship between different pa-
rameters. To identify the primary predictor for SUVmax,
multiple stepwise regression analysis was performed.
Receiver operating characteristics (ROC) curve analysis
was generated that maximized the sensitivity and the
specificity and thus the accuracy for assessing a cut offFigure 2 Group difference of SUVmax. The SUVmax differences among th
type, differentiation, stage as well as (C) expression of 3 biomarkers.** P <
SUVmax = maximal standardized uptake value.value for SUVmax ratio. Differences were considered sig-
nificant when the P value was less than 0.05.
Results
Clinical characteristics
The characteristics of the patients are summarized in
Table 2. The patients’ age ranged from 33 to 81 years
(median age, 62 years). There were 47 men (median age
65 years) and 15 women (median age 60 years) and there
was no difference in ages of these 2 groups (P = 0.095).
The median values of the SUVmax were 7.2 (range, 1 to
20.8), 7.8 (range, 2.2 to 20.8) and 5.7 (range, 1 to 17.1) in
the total, male, and female populations, respectively.
Histological type of NSCLC fell in adenocarcinoma
(n = 40) and squamous cell carcinoma (n = 22). No sig-
nificant difference in SUVmax of the groups with dif-
ferent age (P = 0.077), gender (P = 0.147) or tumor size
(P = 0.064) was observed (Table 2, Figure 2).
The age, tumor size, p53 positivity and ERCC1 positivity
dependent differences in SUVmax
Student t-test and one way ANOVA were performed to
determine the parameter based group differences in
SUVmax (Table 2, Figure 2). In the current study, Stu-
dent t-test revealed significantly higher SUVmax in the pa-
tient population with squamous cell carcinoma (P = 0.045),
p53 positive (P = 0.000) or ERCC positive cancers (P =
0.033), respectively.
One way ANOVA revealed significant difference in the
mean SUVmax of NSCLC with different differentiation
[F (2,61) = 4.126, P = 0.021]. LSD post hoc test revealed
that the difference was derived from the significantly
higher SUVmax from the NSCLC patients with poor
(P = 0.017) differentiation. There was no significant dif-
ference in the SUVmax from poorly and moderately
differentiated tumors (P = 1) or moderately and well dif-
ferentiated tumors (P = 0.132). On the other hand, no
difference in the SUVmax of patients at different clinical
stages [F (3,61) = 0.608, P = 0.612] was observed (Figure 2).e patients with different (A) age, gender and tumor size; (B) cancer
0.01; * P < 0.05; # in (B) *P < 0.05 vs well-differentiation group;
Table 3 Correlation analysis among different parameters
SUVmax p53 ERCC1 Tumor size Long Differentiation Grading Age Gender
Pearson correlation SUVmax 1.000 .508** -.067 .174 .206 -.327** .143 -.118 -.168
p53 .508** 1.000 -.399** .158 .196 -.605** .321** -.106 -.191
ERCC1 -.067 -.399** 1.000 -.181 -.175 .644** -.241* .093 .240*
tumorsize .174 .158 -.181 1.000 .920** -.286* -.017 .170 -.112
long .206 .196 -.175 .920** 1.000 -.323** -.069 .127 -.077
differentiation -.327** -.605** .644** -.286* -.323** 1.000 -.499** .197 .286*
grading .143 .321** -.241* -.017 -.069 -.499** 1.000 -.048 -.206
age -.118 -.106 .093 .170 .127 .197 -.048 1.000 -.030
gender -.168 -.191 .240 -.112 -.077 .286* -.206 -.030 1.000
*, P < 0.05; **, P < 0.01.
Figure 3 Correlationship analysis among the parameters. SUVmax was significantly correlated with p53 IHC score (A, R = 0.508, P = 0.000) or
tumor differentiation (D, R = −0.327, P = 0.005). The IHC score of p53 was significantly correlated with that of ERCC1 (B, R = −0.399, P = 0.001),
tumor differentiation (E, R = −0.605, P = 0.000) or clinical stage (C, R = 0.321, P = 0.006). Furthermore, tumor differentiation was significantly
correlated with ERCC1 IHC score (F, R = 0.644, P = 0.000).
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Table 4 Multiple stepwise regression analysis of primary predictor for SUVmax





R2 Change F Change df1 df2 Sig. F Change
MSR .508 .258 .246 3.84094 .258 20.562 1 59 .000
Predictor: p53; Dependent Variable: SUVmax; MSR: Multiple Stepwise Regression; SUVmax = maximal standardized uptake value.
Figure 4 The receiver operating characteristics (ROC) curve for
the optimal cut-off value of SUVmax in suggesting p53 positive
NSCLC. Area under the curve: 0.769; 95% CI: 0.654 to 0.884; p = 0.000.
A SUVmax ratio of 5.15 or lower suggests a NSCLC to be p53 positive
with a sensitivity of 79.5% and specificity of 47.8%.
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Table 3 demonstrated the correlationship analysis among
the parameters. SUVmax was significantly correlated with
p53 IHC score (R = 0.508, P = 0.000, also see Figure 3A)
or tumor differentiation (R = −0.327, P = 0.005, also see
Figure 3D). Besides SUVmax, p53 IHC score was sig-
nificantly correlated with ERCC1 IHC score (R = −0.399,
P = 0.001, also see Figure 3B), tumor differentiation
(R = −0.605, P = 0.000, also see Figure 3E) or clinical stage
(R = 0.321, P = 0.006, also see Figure 3C). Furthermore,
tumor differentiation was significantly correlated with
other factors including ERCC1 IHC score (R = 0.644,
P = 0.000, also see Figure 3F), tumor long axis (R = −0.323,
P = 0.006), clinical stages (R = −0.499, P = 0.000) or gender
(R = 0.286, P = 0. 013).
Based on the findings that p53 IHC level was closely
related with SUVmax and ERCC1 positive tumors de-
monstrated significantly higher SUVmax, it is reasonable
to hypothesize that SUVmax might be usable in predic-
ting the p53 or ERCC1 related chemotherapy resistance.
Thus, we performed the multiple stepwise regression
analysis to determine which molecule is the primary pre-
dictor for SUVmax.
IHC score of p53 is the primary predictor for SUVmax
Employing the multiple stepwise regression model, we
input the SUVmax as the dependent variable, all the
other parameters including age, gender, tumor size, dif-
ferentiation, clinical stage, IHC score for p53 and ERCC1
as the independent variables. Multiple stepwise reg-
ression analysis revealed that the adjusted R2 for p53
IHC score is 0.246 and the P value is 0.000 (Table 4,
Additional file 1: Figure S1). This statistical finding
strongly suggests that p53 IHC score is the primary pre-
dictor for SUVmax. In another word, the SUVmax reflects
the expression level of p53, thus may offer useful infor-
mation for the p53 related chemotherapy resistance.
The SUVmax greater than 2.5 is often used as a cut-off
value for malignancy. However it has been shown that
there is a significant number of false positivity (due to
inflammatory diseases) and false negativity (due to low-
grade malignancies) in the evaluation of primary tumor
[19]. A recent study suggested that the cut-off value of
SUVmax larger than 5 leads to an optimized diagnosing
sensitivity and specificity of NSCLC [20]. We thus inves-
tigated the sensitivity and specificity at these two cut-off
values.ROC curve analysis revealed that the area under the
curve is 0.769 with the 95% confidence interval (CI) ran-
ging from 0.654 to 0.884 (p = 0.000). When the cut-off
value of SUVmax was set at 2.55, the sensitivity and spe-
cificity of suggesting p53 positive NSCLC were 100%
and 13%, respectively. However, when we set the cut-off
value of SUVmax at 5.15, the sensitivity and specificity of
suggesting p53 positive NSCLC were 79.5% and 47.8%,
respectively (Figure 4).
Discussion
FDG-PET, one of the current-available non-invasive im-
aging methods, has long been used to determine the en-
hanced metabolism in malignant tumor indicated by
increased glucose uptake which is represented by an in-
creased SUVmax. Our study offers further evidence that
the SUVmax of FDG-PET may be a predicting parameter
for some chemotherapy resistant NSCLCs, especially for
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thermore, SUVmax may be the most relevant parameter
for p53 related chemotherapy which suggests the future
clinical application to design the therapeutic plan.
EGFR is a cell surface receptor found primarily on cells
with epithelial origin. EGFR overexpresses in both cell
lines and samples of NSCLC, and contributes to the in-
creased tumor proliferation, poor differentiation, higher
incidence of metastases to lymph nodes and a worse prog-
nosis [21]. Previous studies have demonstrated that ex-
pression status of EGFR can predict treatment response
and survival benefit from the addition of cetuximab to
first-line chemotherapy in patients with advanced NSCLC
[11]. Taylor and colleagues [22] found that there was no
correlation between SUVmax and EGFR expression in
esophageal cancer specimens. Shimizu et al [15] reported
that phosphorylated EGFR-positive cases showed higher
SUVmax than negative cases in lung adenocarcinoma, but
without statistical significance. Our finding is quite con-
sistent with theirs in that there is no relationship between
EGFR expression and SUVmax in NSCLCs. Furthermore,
we did not reveal any difference in the SUVmax between
adenocarcinoma and squamous cell carcinoma. Our study,
together with previous one [15], suggests that FDG-PET
may not be suitable for determining EGFR-related chemo-
therapy resistance or evaluating therapeutic effect of anti-
EGFR treatment for NSCLCs.
The anti-cancer mechanism for the platinum com-
pounds is to form adducts and covalent cross-links bet-
ween DNA double strands and thus effectively block DNA
replication and transcription. ERCC1 can recognize and
remove these adducts and covalent cross-links, thus resist-
ant to platinum agents [12]. A recent meta-analysis indi-
cated that high ERCC1 level was a positive prognostic
factor, being associated with shorter survival and lower re-
sponse to platinum-based chemotherapy in advanced
NSCLC patients [23]. Interestingly, we revealed that the
SUVmax of ERCC1-positive cases were significantly higher
than that of ERCC1-negative cases, there was statistical
correlation between SUVmax and ERCC1 level, but failed
to detect robust correlationship when the multiple step-
wise regression was performed. It is still inconclusive
whether SUVmax can be used to determine ERCC1 related
chemotherapy resistance based on our current study.
As a tumor suppressor gene, p53 is capable of either
arresting the cell cycle or inducing apoptosis. Tumors
expressing p53 were less resistant to cisplatin, carbopla-
tin, paclitaxel, and gemcitabine [10], probably due to the
transcription of some MDR genes in these tumors [24].
A previous study suggested that there was no association
between p53 expression and FDG uptake in 23 resected
NSCLCs [25]. This is inconsistent with our current find-
ing that the mean SUVmax of p53-positive cases was sta-
tistically higher than that of p53-negative cases. Besides,we also offered evidence that p53 expression is the pri-
mary predicting factor for the SUVmax. Our findings lead
to the concept that FDG-PET can be used to represent
p53 expression status, thus predict the p53-related
chemotherapy sensitivity. In the clinic settings, we
should set the cut-off value of SUVmax at around 5 to
get the optimized sensitivity and specificity However,
this is a more like bench study even if we used the cli-
nical imaging technique. Using p53 as the biomarker for
chemotherapy resistance in NSCLC is risky. Thus, cau-
tions should be taken when using the SUVmax of FDG as
an alternative or reliable marker for p53, not to mention
the prognosis of NSCLC. To really apply the SUVmax of
FDG in the clinic settings, more bench studies and clinic
trials are needed. Further efforts are needed to reveal the
underlying reasons for the inconsistency between the
findings of ours and others, the study to fill the gap
between our experimental findings and future clinical
applications should also be considered.
Conclusions
In conclusion, the expressions of p53 and ERCC1 are as-
sociated with the SUVmax on FDG-PET in NSCLCs. Of
the two markers, p53 expression is the primary predictor
for the SUVmax. Based on our findings, FDG-PET might
be a simple and good non-invasive method for predicting
p53-related chemotherapy resistance in NSCLCs. But
cautions should be taken when using this method in the
clinical settings.
Additional file
Additional file 1: Figure S1. Multiple stepwise regression analysis of
the primary predictor for SUVmax.
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